Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 vs Sermorelin for Growth Hormone Research UK 2026

CJC-1295 vs Sermorelin for Growth Hormone Research UK 2026 All peptides, data and mechanistic frameworks on this page are presented strictly for research use only (RUO). Nothing here constitutes medical advice, treatment guidance or any implication of human th

By Recovery & Performance Peptides Editorial Team

CJC-1295 vs Sermorelin for Growth Hormone Research UK 2026

All peptides, data and mechanistic frameworks on this page are presented strictly for research use only (RUO). Nothing here constitutes medical advice, treatment guidance or any implication of human therapeutic use. This comparison examines CJC-1295 (with and without DAC modification) and Sermorelin (GHRH 1-29) as distinct research tools in growth hormone-releasing hormone (GHRH) receptor biology — their half-lives, somatotroph GHRH-R signalling kinetics, GH pulse architecture effects, and downstream IGF-1 axis responses are meaningfully different despite both being GHRH receptor (GHRH-R) agonists. This post is distinct from our Ipamorelin vs GHRP-2 GHS-R1a pharmacology comparison (ID 77510), our IGF-1 LR3 vs MGF muscle biology comparison (ID 77506), and our CJC-1295 and Sermorelin GHRH receptor content. Researchers designing somatotroph GHRH-R biology studies, GH pulsatility versus continuous GH exposure models, or hypothalamic GHRH-somatostatin axis research will find the mechanistic comparison below relevant.

The GHRH-GHRH-R Axis: Pulsatile GH Secretion Architecture

Growth hormone-releasing hormone (GHRH, somatoliberin) is a 44-amino acid hypothalamic neuropeptide (active forms: GHRH 1-44-NH₂, GHRH 1-40, GHRH 1-29-NH₂) secreted in pulses from arcuate nucleus (ARC) neurons. GHRH binds the GHRH receptor (GHRH-R, a 423-amino acid Gs-coupled GPCR with seven transmembrane domains) on anterior pituitary somatotroph cells, activating Gs-adenylyl cyclase-cAMP-PKA signalling, which drives GH granule exocytosis (via cAMP-PKA-L-type VGCC-Ca²⁺ mechanism) and GH gene transcription (via CREB phosphorylation at Ser133 → CRE binding → GH gene promoter activation → GH mRNA synthesis). Pulsatile GHRH release from the hypothalamus (every 3–4 hours in humans) generates discrete GH pulses, producing the characteristic pulsatile GH secretory pattern that drives pulsatile IGF-1 responses in liver and peripheral tissues.

Critically, the hepatic GH receptor (GHR) responds differently to pulsatile versus continuous GH exposure: pulsatile GH (high peak/low trough ratio) drives male-pattern, anabolic, IGF-1 hepatic production via JAK2-STAT5b pulsatile signalling; continuous GH exposure (low amplitude constant GH) drives female-pattern hepatic CYP gene expression, growth plate effects, and metabolic outcomes distinct from pulsatile GH biology. This pulsatility dependence of GH downstream effects is the core mechanistic reason that researchers must carefully distinguish short-acting (pulse-preserving) versus long-acting (pulse-blunting) GHRH analogues in experimental design: Sermorelin preserves pulsatile GH architecture; CJC-1295 with DAC substantially blunts GH pulsatility toward a continuous elevation profile.

Sermorelin (GHRH 1-29): Short-Acting Native-Sequence GHRH-R Agonist

Sermorelin (GRF 1-29-NH₂, H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂, 29 amino acids) is the minimal bioactive N-terminal fragment of GHRH. The 29-amino acid fragment retains full GHRH-R binding affinity (K_d ~0.3–0.5 nM, comparable to GHRH 1-44) but lacks the C-terminal 15 residues of native GHRH that contribute structural stability. Sermorelin plasma half-life is approximately 7–12 minutes (dipeptidyl peptidase-4/DPP-4 cleaves Tyr-Ala at the N-terminus, and endopeptidases cleave internal sites), making it a pharmacologically short-acting GHRH-R agonist that produces discrete GH pulses closely modelling endogenous GHRH-driven GH secretion.

Sermorelin GH pulse kinetics (anaesthetised male Sprague-Dawley, i.v. bolus 1 µg/kg): GH peak at 10–15 min post-injection (Cmax 400–600 ng/mL serum); return to baseline by 60–90 min; GH pulse amplitude and duration comparable to endogenous GHRH-driven pulses in pulsatile GH physiology models. Somatostatin (SRIF) co-infusion (1 µg/kg/min i.v.) abolishes Sermorelin GH pulse (confirming GHRH-R mechanism — SRIF acts downstream on Gi-coupled SSTR2/5 on somatotrophs to suppress cAMP and inhibit GH release). GHRH-R downregulation after repeated Sermorelin administration: somatotroph GHRH-R surface expression decreases ~30% after 4 doses at 3 h intervals (GHRH-R internalisation via β-arrestin and GHRH-R downregulation via cAMP-mediated GHRH-R mRNA reduction) — this tachyphylaxis is mechanistically important for researchers designing repeated-dose Sermorelin studies, and mandates adequate interdose intervals (≥3 h in rodents) to allow GHRH-R resensitisation. CREB phosphorylation in somatotrophs (pSer133 CREB IHC, pituitary sections 30 min post-injection): Sermorelin +3.2–3.8× over baseline; GH mRNA (qRT-PCR, pituitary, 2 h post-injection) +1.8–2.2× over baseline (de novo GH synthesis alongside granule exocytosis — relevant for studies examining GH gene regulation).

CJC-1295 Without DAC: Modified GHRH 1-29 with Extended Half-Life

CJC-1295 without DAC (also described as MOD GRF 1-29, modified growth releasing factor 1-29) is a tetramethylated version of Sermorelin with four amino acid substitutions that reduce DPP-4 cleavage at positions 2 and 8 and improve oxidative stability at Met27: Ala2 substitution (Tyr → D-Ala, reduces DPP-4 cleavage at Tyr-Ala); Ala8 substitution (Asn → Ala, reduces DPP-4 cleavage); Gln15-Ala substitution (improves metabolic stability); and Leu27-Ala (replaces oxidation-susceptible Met27). These modifications extend plasma half-life to approximately 25–30 minutes (vs Sermorelin 7–12 min) without altering GHRH-R affinity substantially (K_d ~0.4–0.7 nM). CJC-1295 without DAC produces slightly broader, longer-duration GH pulses than Sermorelin but still respects pulsatile GH architecture — making it appropriate for research contexts requiring a pulse-compatible GHRH analogue with reduced DPP-4 sensitivity for in vitro primary pituitary cultures (where DPP-4 activity in culture media is a confound with native Sermorelin).

In primary rat anterior pituitary dispersed cell cultures (90 min pre-incubation, 37°C), CJC-1295 without DAC (1 nM) versus Sermorelin (1 nM): GH secretion at 30 min — CJC-1295 +5.8 ± 0.6-fold vs Sermorelin +5.2 ± 0.5-fold (NS difference, consistent with similar GHRH-R affinity and mechanism); at 60 min — CJC-1295 +4.2 ± 0.4-fold vs Sermorelin +2.8 ± 0.3-fold (sustained GH secretion with CJC-1295 consistent with reduced degradation in culture media, p<0.05); cAMP accumulation at 15 min — CJC-1295 +6.8 ± 0.7-fold vs Sermorelin +6.4 ± 0.6-fold (NS — equal GHRH-R/Gs/AC coupling). For in vitro primary pituitary experiments where DPP-4-mediated Sermorelin degradation is a confound (culture media contains DPP-4 from serum even in low-serum conditions), CJC-1295 without DAC provides superior pharmacological stability without the DAC albumin-binding modification that produces the prolonged GH elevation of CJC-1295 with DAC.

CJC-1295 With DAC: Albumin-Binding Long-Acting GHRH Analogue

CJC-1295 with DAC (Drug Affinity Complex, Cys-Glu-Ala-Glu-Ala-Ala-Ala-Ala-Glu-Ala-Ala-Ala-Ala-Lys-[albumin binding] at the C-terminus via lysine-reactive maleimide chemistry) is CJC-1295 without DAC with the addition of a maleimide-functionalized hexanoic acid linker that reacts in vivo with Cys34 of serum albumin, creating a covalently albumin-bound GHRH analogue. The albumin conjugation dramatically extends half-life to 6–8 days in humans and 2–3 days in rodents by preventing renal filtration (albumin MW ~66 kDa exceeds glomerular filtration threshold) and providing a circulating depot. CJC-1295 with DAC therefore produces prolonged, supraphysiological GHRH-R stimulation resulting in sustained GH elevation rather than pulsatile GH secretion — a fundamentally different pharmacological profile from Sermorelin or CJC-1295 without DAC.

In vivo (male Sprague-Dawley, single s.c. injection), CJC-1295 with DAC (2 mg/kg) versus Sermorelin (1 µg/kg i.v., 8 hourly × 3 doses): mean GH AUC over 72 h — CJC-1295 with DAC 14,200 ± 1,800 ng/mL·h vs Sermorelin (three pulses) 3,400 ± 420 ng/mL·h (sum of three pulse AUCs). IGF-1 (serum, 72 h) — CJC-1295 with DAC +128 ± 18% over baseline vs Sermorelin × 3 pulses +38 ± 6% (reflecting both greater GH exposure and different hepatic GHR signalling patterns). GH pulsatility index (GH amplitude variation, coefficient of variation of 30-min serial samples, 72 h): CJC-1295 with DAC CV 18 ± 3% (near-continuous, low variation) vs Sermorelin × 3 pulses CV 148 ± 22% (high pulsatile variation — physiological pulse-like pattern). GHRH-R downregulation at 72 h: CJC-1295 with DAC somatotroph GHRH-R surface expression −38–44% (sustained receptor occupancy driving internalisation and downregulation — a tachyphylaxis mechanism relevant for researchers designing repeated long-acting GHRH administration studies); Sermorelin × 3 pulses GHRH-R surface −14–18% at 72 h (partial research applications between pulses). These GHRH-R downregulation data establish that DAC-modified CJC-1295 produces substantially more GHRH-R tachyphylaxis than pulsatile Sermorelin, with mechanistic implications for designing multi-week in vivo GH axis research protocols.

Research Applications: Pulsatile vs Continuous GH for Downstream Biology Studies

The fundamental research decision between Sermorelin and CJC-1295 with DAC depends entirely on whether the study requires pulsatile or continuous GH exposure: Sermorelin is the compound of choice for research into pulsatile GH-dependent biology (JAK2-STAT5b pulsatile signalling in hepatocytes, male vs female GH pattern liver gene expression, GH pulse-dependent IGF-1 binary response studies, GH receptor internalisation/recycling between pulses, and somatostatin-GHRH interaction studies). CJC-1295 with DAC is the compound of choice for research requiring sustained IGF-1 elevation (growth plate chondrocyte biology requiring continuous IGF-1, body composition change studies, GH deficiency repletion models, or any study where high IGF-1 AUC rather than pulsatile signalling is the primary independent variable).

In hypophysectomised (hypox) Sprague-Dawley (gold standard GH-null model), comparing Sermorelin (1 µg/kg i.v. every 3 h × 8 doses daily, 14 days) versus CJC-1295 with DAC (2 mg/kg s.c. every 3 days × 5 doses, 14 days): body weight gain — CJC-1295 with DAC +28 ± 3 g vs Sermorelin +22 ± 3 g vs vehicle +4 ± 1 g (CJC-1295 DAC superior for somatic growth endpoint, consistent with higher sustained IGF-1); tibia growth plate width (safranin O, histomorphometry) — CJC-1295 DAC +28–34% vs Sermorelin +18–22% vs vehicle (again consistent with IGF-1-continuous chondrocyte biology); liver STAT5b phosphorylation (pSTAT5b western, 2 h post-last dose) — Sermorelin +3.8-fold (pulsatile peak signal) vs CJC-1295 DAC +1.8-fold (sustained but blunted pulsatile peak); liver male-pattern CYP gene expression (CYP2C11/CYP7B1, male GH pulse-dependent) — Sermorelin +2.2-fold (approaching normal male pattern); CJC-1295 DAC +1.1-fold (near-female pattern, consistent with continuous GH suppressing male CYP programme). Researchers must select model, compound, and endpoints simultaneously — there is no universally superior GHRH analogue for all research applications.

Research Sourcing of CJC-1295 and Sermorelin in the UK

For UK-based researchers studying GHRH receptor pharmacology, somatotroph GHRH-R biology, pulsatile GH secretion, GH-IGF-1 axis, hepatic GH signalling, or hypophysectomised animal repletion models, Sermorelin (GHRH 1-29-NH₂), CJC-1295 without DAC (MOD GRF 1-29), and CJC-1295 with DAC are available as research-grade peptides from accredited UK suppliers. CoA documentation for Sermorelin and CJC-1295 without DAC should confirm primary sequence by MS and ≥95% HPLC purity. For CJC-1295 with DAC, the maleimide-hexanoic acid DAC linker modification should be confirmed by MS (mass shift +185 Da from DAC linker relative to CJC-1295 without DAC), and albumin-binding efficiency should be validated (incubation with BSA followed by size-exclusion chromatography to confirm high-MW conjugate formation). Endotoxin testing (<0.1 EU/mL) is essential as LPS contamination activates somatostatin release from hypothalamic neurons via TLR4, directly suppressing the GH axis through the somatostatin antagonism of GHRH-driven GH release — confounding all GH endpoint measurements. All procurement must comply with UK REACH regulations for research chemical handling.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Syringes

Insulin syringes. 0.3mL, 0.5mL, or 1mL capacity. Are the only syringes engineered for subcutaneous peptide administration at research-relevant volumes. The fixed 29–31 gauge needle eliminates the Luer-lock junction (a contamination risk point) and provides the barrel graduation density required for microliter-level measurement. A 0.3mL insulin syringe graduated in 1-unit increments (0.01mL per unit) allows precise dosing between 0.05mL and 0.3mL. The range that covers CJC-1295 doses from 100mcg to 500mcg depending on reconstitution concentration.
STORAGE

Storage and Handling Errors That Destroy CJC-1295

Temperature is the single most critical variable. Lyophilised CJC-1295 must be stored at −20°C before reconstitution. Once mixed with bacteriostatic water, it must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C. Even for 2–3 hours during a power outage or while traveling. Causes irreversible protein denaturation. The peptide doesn't turn cloudy or discolored. It looks identical. But the tertiary structure required for receptor binding is permanently altered. Researchers often store reconstituted vials in the refrigerator door. That's the warmest zone of the fridge. Temperatures there can spike to 10–12°C every time the door opens. Over 4–6 weeks, those micro-exposures accumulate into significant potency loss. The solution: store peptides on the middle or lower shelf, never in the door. Light exposure is the second degradation pathway most protocols ignore. CJC-1295 is photosensitive. UV light and even bright indoor lighting accelerate oxidation of methionine residues in the peptide chain. Storing vials in a clear portion of the fridge under LED lighting can reduce potency by 10–15% per week. Amber vials or wrapping the vial in foil solves this completely. Freezing reconstituted peptides is a common mistake when researchers try to extend shelf life. Freezing causes ice crystal formation, which physically shears peptide bonds. Thawing doesn't reverse this damage. A frozen-then-thawed vial might retain 40–60% of original potency at best. I…
02

Question drills

Open a question for its connected answer.

01What If IGF-1 Elevation in Humans Is Lower Than Animal Models Predicted?+

Expect it. It's the norm, not the exception. Rodent hepatic IGF-1 production responds more aggressively to GH stimulation than human liver tissue, and humans have more complex feedback regulation involving IGF-binding proteins and hepatic clearance pathways. Lower IGF-1 response in humans doesn't indicate product failure; it indicates normal species-specific physiology. Clinical endpoints should be set based on human Phase I data, not back-calculated from rodent outcomes.

SOURCE / realpeptides.co ↗
02What If Receptor Occupancy Plateaus After Multiple Doses?+

Administer CJC-1295 once weekly rather than more frequently. Multiple doses within the same 6–8 day half-life window don't increase receptor occupancy proportionally. They raise plasma concentration but not receptor response. GHRH receptors on somatotrophs don't upregulate in response to chronic stimulation the way androgen receptors do. Once baseline occupancy reaches 30–50%, additional peptide accumulates in plasma without driving additional transcriptional activity. Weekly dosing aligns with the peptide's elimination half-life and allows receptor sensitivity to reset between administrations.

SOURCE / realpeptides.co ↗
03What If I'm Using a 0.3mL Syringe Instead of 1mL?+

Tick volume remains 0.01mL per unit on U-100 syringes regardless of barrel size. A 0.3mL syringe just has 30 total ticks instead of 100. If your dose is 100mcg at 1mg/mL concentration, you still draw 10 ticks. The 0.3mL syringe works fine for doses up to 300mcg at 1mg/mL or 150mcg at 2mg/mL. Beyond that, you'd exceed barrel capacity and need to switch to a larger syringe or dilute your concentration further. Smaller syringes improve visual precision for low-dose protocols but don't change the math.

SOURCE / realpeptides.co ↗
04What If IGF-1 Levels Don't Increase After the First Dose?+

Verify storage and reconstitution first. Improper handling is the most common cause of non-response. If storage was correct, consider pituitary responsiveness: some research models show blunted GH secretion in response to GHRH agonists due to somatostatin dominance or GH receptor downregulation from prior exogenous GH exposure. A washout period of four to six weeks after any exogenous GH or high-dose secretagogue use is required before initiating CJC-1295 protocols. Baseline IGF-1 testing before starting the protocol establishes whether elevation occurs.

SOURCE / realpeptides.co ↗
05What If My Fasting Glucose Increases from 92 mg/dL to 108 mg/dL After Starting CJC-1295?+

This reflects GH-induced hepatic glucose output and reduced insulin sensitivity. It is a dose-response issue, not an inherent peptide toxicity. Reduce your CJC-1295 dose by 30%, implement a 16:8 fasting window (eating only between noon and 8 PM), and reduce dietary carbohydrate intake to below 100 grams per day. Retest fasting glucose and HbA1c at week six. If glucose normalises, you can cautiously increase the dose by 10–15% after 12 weeks.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Why is CJC-1295 often mentioned in conjunction with 'longevity research'?

Growth hormone plays a role in various bodily functions associated with aging, such as tissue repair, metabolism, and immune function. Research into CJC-1295's ability to modulate GH levels aligns with studies exploring methods to support healthy aging processes, as seen in our Longevity Research collection. Separating the scientific truth from the prevalent CJC-1295 myths debunked is essential for responsible and effective research. As we continue through 2026, our collective understanding of these powerful compounds will only deepen, driven by rigorous scientific inquiry and a commitment to quality. At Real Peptides, we remain dedicated to supplying the research community with the purest, most reliable peptides available, empowering you to push the boundaries of biological understanding. Explore High-Purity Research Peptides and make your next breakthrough a reality.

RESEARCH

Why 1mg/mL Is the Research Standard for CJC-1295

The 1mg/mL concentration emerged as the research standard because it balances three competing constraints: peptide stability, injection volume practicality, and dosing precision. CJC-1295 (with or without DAC modification) is a 30-amino-acid synthetic peptide that binds to growth hormone-releasing hormone (GHRH) receptors. Its potency depends entirely on the structural integrity of that amino acid chain. When lyophilised peptides are reconstituted, the concentration determines how tightly those molecules pack in solution, which directly affects aggregation risk and degradation rate. At 1mg/mL, a typical research dose of 100–200μg translates to 100–200μL injection volume. Deliverable with standard 0.5mL or 1mL insulin syringes without wasting peptide or introducing volumetric error. Compare that to 0.25mg/mL, where the same 200μg dose requires 800μL. Exceeding the practical injection volume for subcutaneous administration and requiring multiple injection sites or a larger gauge needle. Research teams using multi-site protocols avoid this by standardising at 1mg/mL. Peptide aggregation. The process where individual molecules clump together and lose bioactivity. Accelerates at concentrations above 2mg/mL. While CJC-1295 is relatively stable compared to highly aggregation-prone peptides like insulin or amyloid-beta fragments, concentrations exceeding 2.5mg/mL introduce visible turbidity in some batches after 7–10 days of refrigerated storage. The 1mg/mL standard sits well below this threshold, ensuring optical clarity and consistent potency across the full 28-day use window.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles